Inozyme Pharma
Biotechnology Research • 
Boston, Massachusetts, United States • 21-50 Employees
Company overview
| Headquarters | 321 Summer St, Suite 400, Boston, Massachusetts 02210, US |
| Phone number | +14155066700 |
| Websites | |
| NAICS | 541714 |
| SIC | 283 |
| Founded | 2016 |
| Employees | 21-50 |
| Socials |
Key Contacts at Inozyme Pharma
Doug Treco
Ceo And Chairman
Richard Macleod
Executive Director Of Clinical Operations
Stefan Riley
Senior Director Of Investor Relations And Corporate Communications
Sebastian Torres
Executive Director, Drug Product & Supply Chain
Christof Schulz
Director, Drug Substance Manufacturing
Li Xu
Senior Director, Qc
Jelena Garafalo
Senior Director Medical Affairs Operations And Evidence Generation
Sarah Myers
Associate Director
Jinyong Huang
Sr. Director, Statistical Programming
Jason Murray
Director, Sterile Drug Product
Inozyme Pharma Email Formats
Inozyme Pharma uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@inozyme.com), used 71.4% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@inozyme.com | 71.4% |
{first initial}.{last name} | j.doe@inozyme.com | 22.9% |
{first initial} | j@inozyme.com | 5.7% |
About Inozyme Pharma
We are a pioneering, clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these metabolites. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.
Inozyme Pharma revenue & valuation
| Annual revenue | $12,500,000 |
| Revenue per employee | $278,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $40,000,000 |
| Total funding | $60,000,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Inozyme Pharma has 26 employees across 11 departments.
Departments
Number of employees
Inozyme Pharma Tech Stack
Discover the technologies and tools that power Inozyme Pharma's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Security
Form builders
JavaScript frameworks
JavaScript libraries
Miscellaneous
Cookie compliance
JavaScript libraries
CDN
Font scripts
JavaScript libraries
United Kingdom
Germany
PortugalFrequently asked questions
4.8
40,000 users
